These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27025644)

  • 21. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
    Goff DA; Nicolau DP
    Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population.
    Courter JD; Kuti JL; Girotto JE; Nicolau DP
    Pediatr Blood Cancer; 2009 Sep; 53(3):379-85. PubMed ID: 19422028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients.
    Shea KM; Cheatham SC; Wack MF; Smith DW; Sowinski KM; Kays MB
    Int J Antimicrob Agents; 2009 Nov; 34(5):429-33. PubMed ID: 19726163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
    Sun HK; Kuti JL; Nicolau DP
    Crit Care Med; 2005 Oct; 33(10):2222-7. PubMed ID: 16215374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Piperacillin pharmacokinetics and target attainment in children with cancer and fever: Can we optimize our dosing strategy?
    Maarbjerg SF; Thorsted A; Kristoffersson A; Friberg LE; Nielsen EI; Wang M; Brock B; Schrøder H
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27654. PubMed ID: 30740885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
    Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
    Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients.
    Han R; Sun D; Li S; Chen J; Teng M; Yang B; Dong Y; Wang T
    Antibiotics (Basel); 2021 Aug; 10(8):. PubMed ID: 34439043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
    Cies JJ; Shankar V; Schlichting C; Kuti JL
    Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimization of β-Lactam Dosing Regimens in Neonatal Infections: Continuous and Extended Administration versus Intermittent Administration.
    Leegwater E; Wewerinke L; de Grauw AM; van Veen M; Storm BN; Kruizinga MD
    Clin Pharmacokinet; 2023 May; 62(5):715-724. PubMed ID: 36972008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis.
    Prescott WA; Gentile AE; Nagel JL; Pettit RS
    P T; 2011 Nov; 36(11):723-63. PubMed ID: 22346306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.
    Kuti JL; Nightingale CH; Quintiliani R; Nicolau D
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):51-7. PubMed ID: 12376031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamic profiling of antimicrobials against Gram-negative respiratory isolates from Canadian hospitals.
    Keel RA; Zhanel GG; Zelenitsky S; Nicolau DP
    Can J Infect Dis Med Microbiol; 2011; 22(4):132-6. PubMed ID: 23205024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
    Kim A; Sutherland CA; Kuti JL; Nicolau DP
    Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Defining standard and high dosages for β-lactam agents administered by intermittent, prolonged or continuous infusion: a PK/PD simulation study.
    Goutelle S; Jullien V; Bru JP; Cattoir V; Gauzit R; Lesprit P; Lina G; Schramm F; Canoui E; Lepeule R
    J Antimicrob Chemother; 2023 Nov; 78(11):2762-2769. PubMed ID: 37796958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.
    Eagye KJ; Kuti JL; Dowzicky M; Nicolau DP
    Clin Ther; 2007 May; 29(5):889-899. PubMed ID: 17697907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002.
    Kiffer CR; Mendes C; Kuti JL; Nicolau DP
    Diagn Microbiol Infect Dis; 2004 Jun; 49(2):109-16. PubMed ID: 15183860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.